- Company
- HCV testing added to the National Health Screening Program
- by Hwang, Byung-woo Jul 8, 2024 05:46am
- The government's decision to introduce the long-discussed hepatitis C antibody testing to the national screening program is expected to have a positive impact on its treatment market. According to industry sources, the decision is encouraging as it enables the first step of identifying hepatitis C patients. However, how to link diagnosis and
- Company
- New PNH drugs introduced into AstraZeneca’s reign
- by Son, Hyung-Min Jul 8, 2024 05:45am
- Competition is in full swing in the paroxysmal nocturnal&160;hemoglobinuria (PNH) market, which is currently dominated by AstraZeneca's treatments such as Soliris and Ultomiris, with the introduction of new drugs that have new mechanisms of action soon to emerge in the market. Recently, Handok's Empaveli is nearing reimbursement in Korea, and N
- Company
- K-Bio receives FDA Orphan Drug Designations with novel drugs
- by Son, Hyung-Min Jul 8, 2024 05:45am
- In the first half of the year, Korean biopharmaceutical companies succeeded in obtaining numerous Orphan Drug Designations. Few patients have rare diseases but developing innovative new drugs can create added value and an exclusive position in the market. In the United States, if a drug is designated as an orphan drug, it is provided seven years
- Company
- Roche Korea starts reimb process for Columvi in Korea
- by Eo, Yun-Ho Jul 8, 2024 05:45am
- The reimbursement listing process for ‘Columvi,' the first bispecific antibody treatment option for lymphoma, will begin in Korea. According to Dailypharm coverage, Roche Korea's CD20-CD3 bispecific antibody for diffuse large B-cell lymphoma (DLBCL) Columvi (glofitamab) is expected to be presented to the Health Insurance Review and Asses
- Company
- "Allowing switching between atopic dermatitis treatments"
- by Hwang, Byung-woo Jul 5, 2024 05:49am
- More options became available with the approval of biologics and JAK inhibitors to treat atopic dermatitis. However, limitations in switching treatments have been indicated to make effective treatments difficult. Opinions have been suggested that the Korean government must follow the global trend as foreign countries do not limit switching be
- Company
- HLB ‘FDA meeting complete...no supplement data required'
- by Son, Hyung-Min Jul 5, 2024 05:48am
- HLB announced on the 2nd that it had completed the meeting with the U.S. Food and Drug Administration (FDA) to resume the license review of its new liver cancer drug. At the meeting, which was attended by HLB's US subsidiary Eleva and Chinese partner Jiangsu Hengrui Pharmaceuticals, the FDA said it "strongly recommends submitting a re-
- Company
- New strength Uptravi may be prescribed at general hospitals
- by Eo, Yun-Ho Jul 5, 2024 05:48am
- A new dosage strength of the pulmonary arterial hypertension treatment Uptravi may now be prescribed at general hospitals in Korea. According to industry sources, the 600㎛ dose of Janssen Korea’s Uptravi (selexipag) passed d the drug committees (DCs) of tertiary hospitals such as the Seoul National University Hospital, Sinchon Severance
- Company
- Celltrion seeks to expand influence in EUR with Remsima SC
- by Hwang, Byung-woo Jul 5, 2024 05:48am
- Celltrion is expanding to expand the drug’s market share with the addition of Remsima SC’s dosing regimens that followed the EMA’s recommendation for the drug’s marketing authorization. The autoimmune disease treatment Remsima SC recently received final approval from the European Commission (EC) for the 'allowance of additional dosing reg
- Company
- Will the shingles market shift affect NIP?
- by Hwang, Byung-woo Jul 4, 2024 05:52am
- The withdrawal of Zostavax from the shingles market is complicating the calculation of the National&160;Immunization Program. In the government's 'National Immunization Program Priorities' study, there had been a large gap between the priorities of live and recombinant shingles vaccines, but with the number of live shingles vaccine options b
- Company
- MBK Partners to acquire Japan pharma for KRW 3 trillion
- by Kim, Jin-Gu Jul 4, 2024 05:52am
- MBK Partners, the largest private equity firm in South Korea, will acquire Japanese company Alinamin Pharmaceutical for JPY 350 billion (around KRW 3.75 trillion). MBK Partners has been actively pursuing M&A in the biopharmaceutical and healthcare sectors in South Korea and overseas. Within the past year and a half, the company acquired M
